

Policy #	Policy Name	Brief Description of Policy Change
UM ONC_1234	Zevalin (ibritumomab tiuxetan)	Annual Review
UM ONC_1235	Doxil (liposomal doxorubicin)	Annual Review
UM ONC_1242	Jakafi (ruxolitinib)	Annual Review
UM ONC_1259	Gazyva (obinutuzumab)	Annual Review
UM ONC_1297	Venclexta (venetoclax)	Annual Review
UM ONC_1302	Tier 1-5 Utilization Management Program	Annual Review
UM ONC_1304	Generic Drugs	Annual Review
UM ONC_1347	Lorbrena (lorlatinib)	Annual Review
UM ONC_1365	Xpovio (selinexor)	Annual Review
UM ONC_1394	Genomic/Genetic/Biomarker/Tumor Marker Tests	Annual Review
UM ONC_1395	Clolar (clofarabine)	Annual Review
UM ONC_1399	Photofrin (porfimer)	Annual Review
UM ONC_1401	Tukysa (tucatinib)	Annual Review
UM ONC_1422	Tepmetko (tepotinib)	Annual Review
UM ONC_1424	Cosela (trilaciclib)	Annual Review
UM ONC_1425	Fotivda (tivozanib)	Annual Review
UM ONC_1455	Scemblix (asciminib)	Annual Review
UM ONC_1458	Enjaymo (sutimlimab-jome)	Annual Review
UM ONC_1477	Orserdu (elacestrant)	Annual Review